Company: Bristol-Myers Squibb Company
Ticker: BMY
Form: 10-K
Filed: 2026-02-11
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Bristol-Myers Squibb Company's gross margin in fiscal year 2025?
Question Type: derived_ratio

Concept: DerivedGrossProfit
Revenues
Answer (Numeric): 71.08
Answer (Display): 71.08%
Unit: percent

Evidence:
[{"chunk_id": "197", "equivalent_chunk_ids": ["197"], "section": "CONSOLIDATED STATEMENTS OF EARNINGS", "supports": ["gross_profit_revenue", "gross_profit_cost", "denominator"], "text": "Dollars in millions, except per share data\nYear Ended December 31,\nNet product sales\n46,756\n46,778\n43,778\nAlliance and other revenues\n1,438\n1,522\n1,228\nTotal Revenues\n48,194\n48,300\n45,006\nCost of products sold\n(a)\n13,936\n13,968\n10,693\nSelling, general and administrative\n7,267\n8,414\n7,772\nResearch and development\n9,951\n11,159\n9,299\nAcquired IPRD\n3,721\n13,373\nAmortization of acquired intangible assets\n3,317\n8,872\n9,047\nOther (income)/expense, net\n1,158\nTotal Expenses\n38,866\n56,679\n36,566\nEarnings/(Loss) before income taxes\n9,328\n8,379\n8,440\nIncome tax provision\n2,272\nNet earnings/(loss)\n7,055\n8,933\n8,040\nNoncontrolling Interest\nNet earnings/(loss) attributable to BMS\n7,054\n8,948\n8,025\nEarnings/(Loss) per common share:\nBasic\n3.47\n4.41\n3.88\nDiluted\n3.46\n4.41\n3.86\n(a)\nExcludes amortization of acquired intangible assets."}]

Derivation: {"denominator": "revenue", "denominator_value": 48194.0, "format": "percentage", "numerator": "gross_profit", "numerator_value": 34258.0, "op": "divide"}